To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT05442060 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: 30 μg OBI-833/100 μg OBI-821
DRUG: Erlotinib (150 mg daily)

Sponsor

OBI Pharma, Inc